GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.
GliaPharm est une entreprise suisse de biotechnologies active dans le développement de traitements de maladies neurologiques et psychiatriques.
L'approche thérapeutique innovante de GliaPharm est de cibler les cellules gliales, ou 'cellules de soutien' des neurones, afin de soutenir et améliorer le métabolisme cérébral dans certaines conditions pathologiques. Notre vision est de devenir leader dans le développement d'agents ciblant les cellules gliales qui agissent comme neuroprotecteurs et maintiennent les fonctions cognitives.
JANUARY 2019
GliaPharm Announces Research Collaboration with TRB Chemedica International
JANUARY 2019
GliaPharm receives support from the FOXG1 Research Foundation and the BLACKSWAN Foundation to uncover the metabolic effect of FOXG1 in astrocytes
JANUARY 2019
We made it to the @hellotmrc Global Finals of #HTChallenge! From 4,500 applications we have been named one of the 7 Industrial Biotech track Finalists competing to win at the #HTSummit! Come hear us pitch in Paris on March 14-15.